Compare CVS Health Corp (CVS) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Tilray Brands Inc — how do they compare? CVS Health Corp trades at $106.52 (market cap $135.48B), while Tilray Brands Inc trades at $4.48 (market cap $540.74M). The key difference: CVS Health Corp is far larger — about 250.5× Tilray Brands Inc's market cap, and CVS Health Corp pays a 2.51% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| CVS | TLRY | |
|---|---|---|
Market Cap | $135.48B | $540.74M |
Sector | Health | Health |
52-Week High | $106.18 | $21.00 |
52-Week Low | $58.75 | $4.31 |
Enterprise Value | $202.02B | $637.89M |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
TLRY trades at $4.46, up 0.9% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $2.19 billion in 2025, with a negative net income margin of -156.67%, though revenue grew to $821.31 million. Analyst consensus is cautious with 65% hold ratings, and recent news highlights expansion in medical cannabis and new product launches.
The outlook remains challenged by persistent losses and high debt levels, but low valuation ratios like P/S of 0.54 and P/B of 0.35 may attract value investors. Key risks include profitability struggles and regulatory uncertainty, while potential catalysts include international expansion and upcoming earnings on July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
